Anzeige
Mehr »
Donnerstag, 02.10.2025 - Börsentäglich über 12.000 News
Starkes Upside-Potenzial: Wachstumsstory mit starken Gehalten und großem Explorationspotenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40YLC | ISIN: US48576U2050 | Ticker-Symbol: 25K0
Tradegate
01.10.25 | 20:50
5,300 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
KARYOPHARM THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
KARYOPHARM THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
5,2505,40014:38
5,2505,40014:05

Aktuelle News zur KARYOPHARM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiKaryopharm Therapeutics Inc.: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)15NEWTON, Mass., Oct. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies...
► Artikel lesen
11.09.Karyopharm Therapeutics Inc. - 8-K, Current Report2
10.09.Karyopharm completes enrollment in phase 3 myelofibrosis trial3
10.09.Karyopharm Therapeutics Inc.: Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis440- Top-Line Results Anticipated in March 2026 - NEWTON, Mass., Sept. 10, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage...
► Artikel lesen
02.09.Karyopharm Therapeutics Inc.: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)64NEWTON, Mass., Sept. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies...
► Artikel lesen
KARYOPHARM Aktie jetzt für 0€ handeln
11.08.Karyopharm outlines $1B peak U.S. revenue opportunity in myelofibrosis with pivotal Phase III data expected by March 202616
11.08.Karyopharm Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans1
11.08.Karyopharm Therapeutics GAAP EPS of -$4.32 misses by $0.29, revenue of $37.93M in-line4
11.08.Karyopharm Therapeutics Inc. - 10-Q, Quarterly Report1
11.08.Karyopharm Therapeutics Inc. - 8-K, Current Report1
11.08.Karyopharm Therapeutics Inc.: Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress393- New Patient Screening for Phase 3 SENTRY Trial in Myelofibrosis Expected to Close This Week; Top-Line Results Anticipated in March 2026 - - Total Revenue was $37.9...
► Artikel lesen
08.08.Earnings Outlook For Karyopharm Therapeutics1
08.08.Karyopharm Therapeutics Q2 2025 Earnings Preview1
01.08.Karyopharm Therapeutics Inc.: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)194NEWTON, Mass., Aug. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies...
► Artikel lesen
16.07.H.C. Wainwright downgrades Karyopharm stock to Neutral amid financial concerns7
16.07.Finanzielle Sorgen bei Karyopharm: H.C. Wainwright stuft Aktie auf "Neutral" herab9
11.07.Karyopharm lays off more workers as hunt for strategic alternatives turns up short2
11.07.Karyopharm lays off more workers as hunt for strategic alternatives turns up short1
11.07.Karyopharm stock tumbles after disclosing failed financing talks2
11.07.Karyopharm Therapeutics Inc. - 8-K, Current Report6
Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,4